Jin-Hee Park1, Yong Sik Jung2, Young-Mi Jung3, Sun Hyoung Bae4. 1. College of Nursing· Research Institute of Nursing Science, Ajou University, 164, World cup-Ro, Yeongtong-Gu, Suwon, 16499, Republic of Korea. 2. Department of Surgery, School of Medicine, Ajou University, Suwon, Republic of Korea. 3. Department of Nursing, School of Medicine, Cheongju University, Cheongju, Republic of Korea. 4. College of Nursing· Research Institute of Nursing Science, Ajou University, 164, World cup-Ro, Yeongtong-Gu, Suwon, 16499, Republic of Korea. shyoung@ajou.ac.kr.
Abstract
PURPOSE: Cancer patients who underwent chemotherapy experience cognitive decline, which, in turn, negatively impacts quality of life (QoL). Depression is considered a psychological factor that is negatively associated with the QoL of cancer patients. However, the relationships among cognitive functioning, depression, and QoL in breast cancer patients are under-researched in the literature. The aim of this cross-sectional study was to identify the role of depression in the relationship between cognitive functioning and QoL among breast cancer patients. METHODS: One hundred thirty breast cancer patients who underwent primary treatment participated. Participants completed the Functional Assessment of Cancer Therapy-Cognitive Function version 3, the Montreal Cognitive Assessment, the Beck Depression Inventory-II, and the Functional Assessment of Cancer Therapy-Breast Scale. The data were analyzed using multiple regression according to Baron and Kenny's strategies and the Sobel test. RESULTS: Subjective and objective cognitive functioning and depression were statistically significant predictors of QoL in breast cancer patients. Depression played a partial mediating role in the relationship between objective cognitive functioning and QoL and between subjective cognitive functioning and QoL. Additionally, the Sobel test demonstrated that depression had a significant partial mediating effect between subjective cognitive functioning and QoL (Z = 4.91, p < 0.001) and between objective cognitive functioning and QoL (Z = 2.62, p = 0.009). CONCLUSIONS: The findings indicated that depression could influence the association between cognitive functioning and QoL in breast cancer patients. Healthcare providers should develop an intervention focused on decreasing depression to evaluate the effectiveness of improving quality of life for breast cancer patients with cognitive dysfunction.
PURPOSE:Cancerpatients who underwent chemotherapy experience cognitive decline, which, in turn, negatively impacts quality of life (QoL). Depression is considered a psychological factor that is negatively associated with the QoL of cancerpatients. However, the relationships among cognitive functioning, depression, and QoL in breast cancerpatients are under-researched in the literature. The aim of this cross-sectional study was to identify the role of depression in the relationship between cognitive functioning and QoL among breast cancerpatients. METHODS: One hundred thirty breast cancerpatients who underwent primary treatment participated. Participants completed the Functional Assessment of Cancer Therapy-Cognitive Function version 3, the Montreal Cognitive Assessment, the Beck Depression Inventory-II, and the Functional Assessment of Cancer Therapy-Breast Scale. The data were analyzed using multiple regression according to Baron and Kenny's strategies and the Sobel test. RESULTS: Subjective and objective cognitive functioning and depression were statistically significant predictors of QoL in breast cancerpatients. Depression played a partial mediating role in the relationship between objective cognitive functioning and QoL and between subjective cognitive functioning and QoL. Additionally, the Sobel test demonstrated that depression had a significant partial mediating effect between subjective cognitive functioning and QoL (Z = 4.91, p < 0.001) and between objective cognitive functioning and QoL (Z = 2.62, p = 0.009). CONCLUSIONS: The findings indicated that depression could influence the association between cognitive functioning and QoL in breast cancerpatients. Healthcare providers should develop an intervention focused on decreasing depression to evaluate the effectiveness of improving quality of life for breast cancerpatients with cognitive dysfunction.
Entities:
Keywords:
Breast neoplasms; Cognition; Cognitive dysfunction; Depression; Quality of life
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Vincent Koppelmans; Monique M B Breteler; Willem Boogerd; Caroline Seynaeve; Chad Gundy; Sanne B Schagen Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544
Authors: N Biglia; V E Bounous; A Malabaila; D Palmisano; D M E Torta; M D'Alonzo; P Sismondi; R Torta Journal: Eur J Cancer Care (Engl) Date: 2011-12-28 Impact factor: 2.520
Authors: Amanda D Hutchinson; Jessica R Hosking; Ganessan Kichenadasse; Julie K Mattiske; Carlene Wilson Journal: Cancer Treat Rev Date: 2012-06-02 Impact factor: 12.111
Authors: Osama Abdalkareem Abdalrahman; Elham H Othman; Anas H Khalifeh; Khaled Hasan Suleiman Journal: Support Care Cancer Date: 2022-06-11 Impact factor: 3.359
Authors: Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi Journal: J Pain Symptom Manage Date: 2020-01-15 Impact factor: 3.612
Authors: Konstantina G Yiannopoulou; Aikaterini I Anastasiou; Konstantinos Kontoangelos; Charalambos Papageorgiou; Ioannis P Anastasiou Journal: Curr Urol Date: 2020-12-18
Authors: Min Kyeong Jang; Sung Hae Kim; Yun Hee Ko; Jeehee Han; Soo Yeon Kim; Sue Kim Journal: Integr Cancer Ther Date: 2022 Jan-Dec Impact factor: 3.279